Purpose: To report the identification of the collagen, type XVII, alpha 1 (COL17A1) c.3156C.T mutation associated with epithelial recurrent erosion dystrophy (ERED) in a Thai family.
Results:
The 67-year-old proband and her 4 siblings were examined by slit-lamp biomicroscopy, which identified bilateral subepithelial opacities in the proband and in one of the 4 siblings. In both the proband and the affected sister, screening of the COL17A1 gene identified a heterozygous c.3156C.T synonymous mutation that has been previously demonstrated to introduce a cryptic splice donor site, likely leading to aberrant splicing of COL17A1. This mutation was not identified in the unaffected siblings, and no mutations were identified in exons 4 and 12 of the transforming growth factor b-induced gene in any of the screened family members.
Conclusions: ERED associated with a COL17A1 mutation has been previously reported in only 6 families, all white. Identification of the c.3156C.T mutation, previously identified in 5 of these 6 families, in the Thai family we report indicates conservation of the genetic basis of ERED across different races and underscores the importance of ophthalmologists around the globe being familiar with ERED, which has only recently become a recognized corneal dystrophy.
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(Cornea 2018;37:909-911) E pithelial recurrent erosion dystrophy (ERED; Online Mendelian Inheritance in Man 122400) is an autosomal dominant disorder that is characterized by recurrent corneal epithelial erosions secondary to impaired epithelial adherence. Developing in childhood, the recurrent corneal erosions lead to subepithelial scarring and fibrosis, which may be mistaken for dystrophic deposits. 1,2 By 30 to 40 years of age, the severity and frequency of corneal erosions decrease, although the resultant epithelial irregularity leads to impaired vision. 3 Given clinicians' unfamiliarity with ERED and the absence of dystrophic corneal opacities in affected individuals, most affected individuals are either misdiagnosed or not given a specific diagnosis.
Although more than a dozen families have been clinically diagnosed with ERED, 2-11 COL17A1 mutations have been identified in only 6 families to date: 1 American family originally reported by Yee et al that we subsequently reported with the c.3156C.T mutation 9 ; 1 Swedish family reported by Jonsson et al 10 with the c.2816C.T mutation; and 2 families from New Zealand, 1 from the United Kingdom, and 1 from Tasmania, Australia, reported by Oliver et al, 11 all with the c.3156C.T mutation. We report the identification of the COL17A1 c.3156C.T mutation in a Thai family affected with ERED, representing the seventh pedigree confirmed to have ERED, and the first nonwhite family.
MATERIALS AND METHODS

Ethics Statement
Researchers followed the guidelines set by the Declaration of Helsinki in the treatment of the patients reported in this study. Written informed consent was obtained from all participants of the study in accordance with the regulations provided by the Institutional Review Board at the University of California at Los Angeles (UCLA IRB#11-000020).
family members to identify clinical features characteristic of ERED. 9, 12 Saliva samples were collected from each enrolled individual using the Oragene Saliva Collection Kit (DNA Genotek Inc, Ottawa, Canada), and genomic DNA was isolated using the Oragene prepIT-L2P Kit (DNA Genotek Inc).
PCR and Sanger Sequencing
Using previously published primers and PCR conditions, the region of COL17A1 containing the c.3156C.T variant was screened in each of the enrolled family members. 9 PCR products were sequenced by Sanger sequencing and were compared with the COL17A1 reference sequence NG_007069.1. To exclude Reis-Bücklers corneal dystrophy (RBCD) and Thiel-Behnke corneal dystrophy (TBCD), exons 4 and 12 of TGFBI were also screened using previously reported primers and PCR conditions. 13 PCR sequences were compared with the TGFBI reference sequence NG_012646.1.
RESULTS
Clinical Characteristics
The proband, a 67-year-old Thai woman (Fig. 1, III-1 ), presented with a 4-decade history of recurrent ocular discomfort and progressive decrease in vision in both eyes. Corrected distance visual acuity measured 20/70 OD and 20/ 100 OS. Slit-lamp examination revealed bilateral, scattered gray-white subepithelial nodules, primarily involving the central 8 mm of each cornea, and diffuse subepithelial scarring (Fig. 2) . The proband's 62-year-old sister (Fig. 1,  III-3 ) reported a 10-year history of recurrent ocular discomfort and mild decrease in vision in each eye and underwent phototherapeutic keratectomy in the left eye 1 year before presentation. Corrected distance visual acuity measured 20/25 OD and 20/30 OS. Slit-lamp examination revealed bilateral, patchy gray-white subepithelial scarring, more in the right eye than in the left eye, with a few gray-white subepithelial nodules in the right eye (Fig. 2) . The proband's 3 other siblings (Fig. 1, III-2 , III-4, III-5) denied a history of symptoms consistent with recurrent corneal erosions and The sixty-seven-year-old proband (Fig.  1, III-1) demonstrates bilateral, scattered gray-white subepithelial nodules and diffuse subepithelial scarring in the right (A) and left (B and C) eyes. The sixty-two-year-old sister of the proband (Fig. 1, III-3) demonstrates bilateral, patchy gray-white subepithelial scarring, more in the right eye (D and F) than in the left eye (E). decreased vision. Slit-lamp examination of each demonstrated bilaterally clear corneas. The proband's father and paternal grandfather, both deceased, also had a history of decreased vision since early adulthood. Ocular examination records were not available for either.
TGFBI and COL17A1 Screening
Given the history of recurrent corneal erosions associated with bilateral, axially distributed subepithelial opacification in the proband and her sister, a TGFBI dystrophy, such as RBCD and TBCD, and ERED were suspected. Therefore, DNA was collected from the proband, as well as her affected and unaffected siblings, for screening of TGFBI and COL17A1. Screening of TGFBI exons 4 and 12 in the proband did not identify any sequence variants. Screening of COL17A1 exon 46 identified the previously reported c.3156T.C mutation in the heterozygous state in the proband and her affected sister but not in any of their unaffected siblings (Fig. 1) .
DISCUSSION
Three different corneal dystrophies, Franceschetti corneal dystrophy, Dystrophia Smolandiensis, and Dystrophia Helsinglandica, all of which are characterized by the development of erosions in the first decade of life, followed by progressive subepithelial fibrosis, have been grouped together by the International Committee for Classification of Corneal Dystrophies (IC3D) as ERED. 14 Although the genetic basis of these 3 corneal dystrophies remains unknown, the similarity of the clinical phenotype of these dystrophies to that observed in ERED associated with a COL17A1 mutation indicates that these dystrophies likely share the same common genetic basis as the more recently reported families with ERED. [9] [10] [11] ERED is likely a more common clinical entity than the small number of families reported with the dominantly inherited disorder would suggest. Given clinician unfamiliarity with the disorder and the same dominant inheritance pattern, similar clinical course and phenotypic features as RBCD and TBCD, affected individuals are likely misdiagnosed with a TGFBI dystrophy. An example of this is the family diagnosed with presumed TBCD that was mapped to chromosome 10q23-q24, in which we subsequently identified the c.3156C.T synonymous mutation in COL17A1, leading to reclassification of this family as having ERED. 9 In addition, the diagnosis of ERED may be more challenging to make, given that it is not associated with dystrophic deposit formation in a characteristic, recognizable pattern. Instead, corneal opacification that develops is secondary to a variable scarring response after recurrent corneal erosion formation, which may differ significantly between affected individuals.
These diagnostic challenges underscore the utility of molecular genetic analysis in the accurate diagnosis of corneal dystrophies with overlapping and variable clinical features. The fact that only 2 pathogenic COL17A1 mutations have been identified in the 7 families screened to date indicates conservation of mutations, as observed for the TGFBI dystrophies, that facilitates diagnostic genetic testing. However, for molecular genetic analysis to be successfully incorporated into clinical practice, clinicians must understand in which clinical scenarios it may effectively differentiate between 2 or more suspected corneal dystrophies, as well as between dystrophic and nondystrophic corneal disorders. As this requires a familiarity with the less common inherited corneal disorders, such as ERED, we report only the seventh family with ERED associated with a mutation in COL17A1 (the sixth associated with the c.3156C.T synonymous mutation) and the first non-white family with ERED. We hope that this report will encourage clinicians to incorporate molecular genetic analysis in their practices and to expand our understanding of the genetic basis of ERED by reporting additional families with previously identified and novel mutations. We also encourage the investigators who have reported families affected with Franceschetti corneal dystrophy, Dystrophia Smolandiensis, and Dystrophia Helsinglandica to screen COL17A1 in these families to determine whether a common genetic basis exists for all of the dystrophies that have been categorized as ERED.
